CD19 and neoplasm: For analysis of cytokine release, T cells genetically engineered to express either only EGFP (vector control), UniCAR stop or UniCAR CD28/ζ were cultivated with or without tumor cells at an e:t ratio of 5:1, either in the presence or absence of 30 nM of anti-CD19 TM for 24h.